Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Dec 15;120(24):4006-7.
doi: 10.1002/cncr.28947. Epub 2014 Aug 13.

Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab

Charles L Bennett  1 , Scott D Newsome, Oliver Sartor, Kenneth R Carson
Affiliations
Comment

Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab

Charles L Bennett et al. Cancer. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES

Dr. Newsome participated in scientific advisory boards for Biogen Idec and Genzyme, and received research support from Biogen Idec and Novartis that was paid directly to his institution for work performed outside of the current study. Dr. Carson received fees for consulting and participation in a Speakers Bureau from Genentech for work performed outside of the current study.

Comment on

References

    1. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80:1430–1438. - PMC - PubMed
    1. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–4840. - PMC - PubMed
    1. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10:816–824. - PubMed
    1. US Food and Drug Administration. Package Insert for Rituximab. accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf. Accessed July 3, 2014.
    1. Norris LB, Georgantopoulos P, Rao GA, et al. Association between rituximab use and progressive multifocal leukoencephalopathy among non-HIV, non-Hodgkin lymphoma Veteran’s Administration patients. Presented at 2014 American Society of Clinical Oncology Annual Meeting; May 30–June 3, 2014; Chicago, IL. meetinglibrary.asco.org/content/132159-144. Accessed July 3, 2014.

MeSH terms

Substances

LinkOut - more resources